Consequently, the screening of CRC for the detection of gene rearrangements involving the NTRK1, NTRK2 and NTRK3 genes has the ability to identify a limited subset of patients able to derive benefit from treatment with entrectinib or other targeted inhibitors. Here, NTRK1 is linked to colorectal carcinoma.